Key facts
- This page summarizes Joshua Richardson's Form 4 filing for Sierra Oncology, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Jan 2022, 20:22.
Joshua Richardson - 25 Jan 2022 Form 4 Insider Report for Sierra Oncology, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 25 Jan 2022
- Net transaction value
- -$13,063,697
- SEC form
- 4
- Accepted by SEC
- 27 Jan 2022, 20:22:18 UTC
- Prior SEC filing
- 09 Jun 2021
- Next SEC filing
- 02 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua Richardson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joshua Richardson filed Form 4 for Sierra Oncology, Inc. on 27 Jan 2022.
Change
- Previous filing in this sequence was filed on 09 Jun 2021.
- Current net transaction value: -$13,063,697.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SRRA
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $6,434,353
- Shares
- +487,451
- Change %
- +33%
- Price
- $13.20
- Shares after
- 1,964,771
- Date
- 25 Jan 2022
- Ownership
- By Longitude Venture Partners III, L.P.
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SRRA
transaction
Derivative
Series B Warrants
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $19,498,050
- Shares
- -1,477,125
- Change %
- -100%
- Price
- $13.20
- Shares after
- 0
- Date
- 25 Jan 2022
- Ownership
- By Longitude Venture Partners III, L.P.
- Underlying class
- Common Stock
- Underlying amount
- 487,451
- Exercise price
- $13.20
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Longitude Capital Partners III, LLC ("LCP III") is the general partner of Longitude Venture Partners III, L.P. ("LVP III") and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and the Reporting Person, a member of the Issuer's board of directors, are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and the Reporting Person disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Footnote F2
Consists of 1,477,125 Series B Warrants held by LVP III which are exercisable for an aggregate of 487,451 shares of Common Stock.